intermediate12 min read

Risk Management for Biotech Investors

Reviewed by Blane Jackson, DDS, MBA. Educational guide only. See the editorial policy and disclosures.

Biotech investing can be thrilling — a single FDA approval can turn a penny stock into a multi-bagger overnight. But that same binary event can also wipe out 80% of your investment in a single afternoon. The key to surviving and thriving in this sector isn't just picking the right drug; it's managing risk so that one bad bet doesn't sink your portfolio. In this guide, you'll learn how to size your positions, prepare for binary events like FDA decisions, allocate your portfolio to balance risk and reward, and use stop-losses effectively without getting shaken out of winners. By the end, you'll have a concrete framework to protect your capital while still capturing biotech's upside.

Position Sizing: The Golden Rule of Biotech Investing

Position sizing is the most important risk management tool you have. In biotech, even the best-researched stock can gap down 50% on a failed trial. If you've put 20% of your portfolio into that stock, you've just lost 10% of your total capital. That's a huge hit to recover from. A common rule of thumb is to risk no more than 1-2% of your total portfolio on any single biotech stock. For a $100,000 portfolio, that means a maximum position of $1,000-$2,000. This might feel small, but it ensures that a single failure won't devastate you. Another approach is to size based on your conviction and the stage of the company. Early-stage, binary-event-driven stocks (like those awaiting Phase 2 data) deserve smaller positions than later-stage companies with multiple shots on goal. For example, a Phase 1 company with one drug might warrant a 1% position, while a Phase 3 company with a strong balance sheet and a partnered drug might warrant 3-4%. The key is to decide your position size before you buy, based on the potential downside, not the potential upside.

Key takeaway

Never risk more than 1-2% of your portfolio on a single biotech stock, and adjust position size based on the stage and risk profile of the company.

Example

Imagine you have a $50,000 portfolio. You're excited about a small-cap biotech with a PDUFA date next month. If you put $5,000 (10%) into it and the FDA issues a Complete Response Letter (CRL), the stock might drop 70%, leaving you with $1,500. That's a $3,500 loss — 7% of your portfolio. If instead you had invested $1,000 (2%), your loss would be $700, just 1.4% of your portfolio. You'd have plenty of capital left to invest in other opportunities.

Binary Events: Preparing for the FDA Decision

Binary events are moments when a stock's fate hinges on a single outcome — like an FDA approval decision, a clinical trial readout, or a Data Safety Monitoring Board (DSMB) recommendation. These events can cause massive price swings, often 50% or more in either direction. To manage risk around binary events, you need a plan before the event occurs. First, decide in advance what you'll do if the news is positive and if it's negative. Will you sell half your position on a positive result to lock in gains? Will you hold through a negative result hoping for a rebound? Many investors use a 'sell half on double' strategy: if the stock doubles on good news, sell half to recoup your initial investment, letting the rest ride risk-free. On the downside, set a mental stop-loss or a limit order to sell if the stock drops below a certain level. But beware: in the chaos of a binary event, the stock might gap down so fast that your stop-loss doesn't execute at your price. That's why position sizing is so critical — it ensures that even a worst-case scenario doesn't ruin you. Another tactic is to avoid holding through binary events altogether if you're not comfortable with the risk. You can always re-enter after the dust settles.

Key takeaway

Have a pre-defined plan for every binary event: decide your actions for both positive and negative outcomes, and consider selling half on a double to lock in gains.

Example

In 2021, the FDA was deciding on Biogen's Alzheimer's drug aducanumab. The stock had been volatile in the months leading up to the decision. Investors who had a plan: if approved, they'd sell half their shares at the open; if not approved, they'd sell all. When the FDA approved the drug (despite controversy), the stock initially jumped but then gave back gains over the following weeks. Those who sold half at the open locked in profits, while those who held all saw the stock eventually fall below pre-approval levels.

Ready to start? Open a Webull account and trade biotech stocks commission-freevia Webull · Affiliate

Portfolio Allocation: Building a Diversified Biotech Basket

Diversification is crucial in biotech because individual drug failures are common. Even the best clinical trials have a 10-20% chance of failure in Phase 3. To mitigate this, you should spread your investments across multiple biotech stocks, different therapeutic areas, and different stages of development. A well-diversified biotech portfolio might include 10-20 positions. But don't just buy any biotech — be strategic. Consider allocating across: (1) Large-cap biotechs with approved products and deep pipelines (like Amgen, Gilead) for stability; (2) Mid-cap companies with late-stage drugs and partnerships (like Vertex, Alnylam) for growth; (3) Small-cap or micro-cap companies with high-risk, high-reward potential (like many clinical-stage companies). Also, diversify by therapeutic area: don't put all your money into oncology or gene therapy. If you have 10 positions, maybe 3 are oncology, 2 are rare disease, 2 are neurology, and 3 are other areas. Additionally, consider non-biotech assets (like index funds or bonds) to balance your overall portfolio. A common rule is to limit biotech to 20-30% of your total portfolio, with the rest in diversified assets. Within your biotech allocation, you can further diversify by market cap and stage.

Key takeaway

Spread your biotech investments across 10-20 stocks, different therapeutic areas, and various stages of development, and keep biotech as a minority of your overall portfolio.

Example

An investor with a $100,000 portfolio might allocate $25,000 (25%) to biotech. Within that, they might put $10,000 in a large-cap biotech ETF, $5,000 in a mid-cap like Vertex, $5,000 in a small-cap with a Phase 3 drug, $3,000 in a Phase 2 company, and $2,000 in a Phase 1 company. This way, if the Phase 1 company fails, they lose only $2,000 (2% of total portfolio), but if it succeeds, they could see a 5x return.

Stop-Loss Strategies: Protecting Your Downside

Stop-loss orders are a tool to limit losses by automatically selling a stock when it falls below a certain price. In biotech, they can be tricky because volatility can trigger them prematurely. For example, a stock might dip 10% on a bad day of trading only to rebound 20% the next week. If you set a tight stop-loss, you'll be sold out and miss the recovery. A better approach is to use a trailing stop-loss, which adjusts upward as the stock price rises. For biotech, a trailing stop of 20-25% is often recommended to allow for normal fluctuations. However, for binary events, stop-losses may not protect you because the stock can gap down below your stop price, and you'll sell at the open at a much lower price. That's why position sizing is more important than stop-losses for binary events. Another strategy is to use a mental stop-loss: you decide in advance that if the stock drops 30% from your purchase price, you'll sell, but you don't place an actual order. This gives you flexibility to reassess if the drop is due to market-wide sell-off or company-specific news. For example, if a biotech drops 30% because the whole market is down, you might hold; if it drops 30% because a trial was halted, you'd likely sell. Remember, stop-losses are not a substitute for research — they're a safety net.

Key takeaway

Use trailing stop-losses of 20-25% for biotech stocks, but rely on position sizing to protect against binary event gaps, and consider mental stops for flexibility.

Example

Suppose you buy a biotech stock at $50. You set a trailing stop-loss at 25%, meaning if the stock falls to $37.50, you'll sell. The stock rises to $80, so your stop-loss moves up to $60. If the stock then drops to $60, you'll sell and lock in a 20% gain. This protects your profits while giving the stock room to fluctuate.

Key terms

Binary Event

An event with two possible outcomes, such as an FDA approval or rejection, that can cause a stock to move dramatically in one direction or the other.

Position Sizing

The process of determining how much capital to allocate to a particular investment, based on risk tolerance and the potential downside.

Stop-Loss Order

An order to sell a stock automatically when it falls to a specified price, designed to limit losses.

Trailing Stop-Loss

A stop-loss order that adjusts upward as the stock price rises, locking in gains while allowing for normal price fluctuations.

Complete Response Letter (CRL)

A formal notification from the FDA that a drug application cannot be approved in its current form, often leading to a significant stock price drop.

Data Safety Monitoring Board (DSMB)

An independent committee that monitors the safety and efficacy of a clinical trial, and can recommend stopping a trial early for safety or efficacy reasons.

PDUFA Date

The date by which the FDA must make a decision on a drug application, often a major catalyst for biotech stocks.

Next steps

Calculate your maximum position size for any biotech stock using the 1-2% rule. For a $50,000 portfolio, that's $500-$1,000 per stock.

Before your next biotech investment, write down a plan for both positive and negative outcomes for the next major catalyst (e.g., FDA decision, trial data).

Review your current portfolio and ensure you have at least 10 different biotech positions, diversified by stage and therapeutic area.

Set a trailing stop-loss of 20-25% on your existing biotech positions, but be aware of the risks during binary events.

If you're holding a biotech stock through a binary event, decide in advance whether you'll sell half on a double or hold all shares.

Put this guide to work

Use these free ClinicalInvestor tools to apply what you just learned.

2026 PDUFA Calendar →

Every FDA decision in 2026 with AI investor analysis.

Biotech Catalyst Calendar →

PDUFA dates, Phase 3 readouts, AdComs, and conferences. Free.

Trial Translator →

Paste any ClinicalTrials.gov ID and get a plain-English AI breakdown.

Biotech Screener →

Filter published biotech profiles by area, phase, market cap, and runway.

Company Profiles →

Pipelines, bull and bear cases, and next expected data for every covered biotech.

Keep learning

How to Invest in Biotech Stocks →PDUFA Dates Explained →Clinical Trial Phases Explained →Biotech Stock Catalysts Guide →